NeuroMetrix, Inc. (NURO)
| Previous Close | 4.4100 |
| Open | 4.5750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.5750 - 4.6300 |
| 52 Week Range | 2.7000 - 11.5200 |
| Volume | |
| Avg. Volume | 50,519 |
| Market Cap | 9.096M |
| Beta (5Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.2700 |
| Earnings Date | May 01, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 28, 2007 |
| 1y Target Est | N/A |
Simply Wall St.NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year
Key Insights NeuroMetrix to hold its Annual General Meeting on 30th of April CEO Shai Gozani's total compensation...
GlobeNewswireNeuroMetrix Announces Steps Taken to Enhance Shareholder Value
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22
- GlobeNewswire
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age
